CD200 Receptor Monoclonal Antibody (OX110), APC, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody OX110 recognizes mouse CD200R also known as OX2
• CD200R is an inhibitory receptor with a similar structure as its ligand, CD200, yet lacks an ITIM domain typically found in inhibitory receptors
• Instead the CD200R cytoplasmic domain contains a novel phosphotyrosine binding domain NPXY, which after binding SHIP inhibits ERK, JNK and MAPK p38 pathways
• In activated macrophages signaling results in inhibition of TNFalpha secretion
• Expression is restricted to hematopoietic cells: myeloid cells (monocytes, macrophages, DCs, neutrophils, mast cells and basophils) and a subset of lymphocytes as well as langerhans (LC) cells and dendritic epidermal T cells
• Applications Reported: This OX110 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This OX110 antibody has been tested by flow cytometric analysis of Fc-blocked mouse thioglycolate-elicited peritoneal cells
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD200R (OX2R) is a receptor for the OX-2 membrane glycoprotein, and both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains
• CD200R is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal
• In mouse, CD200R is expressed primarily by peripheral blood monocytes and neutophils but also by other leucocytes including T-lymphocytes and mast cells
• Further mouse studies of a gene related to CD200R suggests that the receptor may control myeloid function in a tissue-specific manner
• Alternative splicing of CD200R results in multiple transcript variants
• Diseases associated with CD200R dysfunction include primary hypertrophic osteoarthropathy.